Literature DB >> 28486230

The Rise of Expanded Hemodialysis.

Claudio Ronco1.   

Abstract

The low water permeability feature of original cellulosic membranes was considered an advantage in the absence of dialysis equipment that are capable of controlling water removal. The advent of ultrafiltration control systems led to the development and use of high-flux (HF) membranes that allowed improved middle molecule removal including β-2 microglobulin. Further advances in technology allowed better control over the structure and permeability of membranes. Different polymers and improved spinning modalities led to significant advances in solute removal and hemocompatibility. Inner surface modification produced a reduction in membrane thrombogenicity and protein-membrane interaction with a less tendency to fouling and permeability decay. Further evolution in technology led to the development of a new class of membranes referred to as protein-leaking membranes or super-flux or high cutoff (HCO). These membranes are more permeable than conventional HF membranes and allow some passage of proteins, including albumin. The rationale for these membranes is the need for increased clearance of low molecular weight proteins and protein-bound solutes. However, albumin loss in protein-leaking HCO membranes represents a limitation whose effect in patients is still controversial. The last evolution in the field of membranes is the development of a new class defined as "high retention onset" (HRO) due to the peculiar high sieving value in the middle to high molecular weight range. The introduction of HRO membranes in the clinical routine has enabled the development of a new concept therapy called "expanded hemodialysis." Its simple set up and application offer the possibility to use it even in patients with suboptimal vascular access or even with an indwelling catheter. The system does not require particular hardware or unusual nursing skill. The quality of dialysis fluid is, however, mandatory to ensure a safe conduction of the dialysis session. This new therapy is likely to modify the outcome of end-stage kidney disease patients, thanks to the enhanced removal of molecules traditionally retained by current dialysis techniques.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28486230     DOI: 10.1159/000476012

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  23 in total

Review 1.  A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.

Authors:  Valentina Pistolesi; Santo Morabito; Francesca Di Mario; Giuseppe Regolisti; Chiara Cantarelli; Enrico Fiaccadori
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  Flummoxed by flux: the indeterminate principles of haemodialysis.

Authors:  Sudhir K Bowry; Fatih Kircelli; Madhukar Misra
Journal:  Clin Kidney J       Date:  2021-12-27

Review 3.  Effects of Medium Cut-Off Polyarylethersulfone and Polyvinylpyrrolidone Blend Membrane Dialyzers in Hemodialysis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Yu-Hui Hung; Tai-Shuan Lai; Mohamed Belmouaz; Ya-Chun Tu; Chun-Fu Lai; Shuei-Liong Lin; Yung-Ming Chen
Journal:  Membranes (Basel)       Date:  2022-04-20

4.  Expanded hemodialysis as effective alternative to on-line hemodiafiltration: A randomized mid-term clinical trial.

Authors:  Fernando Hadad-Arrascue; Lars-Göran Nilsson; Angela S Rivera; Angelito A Bernardo; Juan B Cabezuelo Romero
Journal:  Ther Apher Dial       Date:  2021-06-29       Impact factor: 2.195

Review 5.  Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist's Opinion.

Authors:  Guido Gembillo; Rossella Siligato; Valeria Cernaro; Domenico Santoro
Journal:  J Clin Med       Date:  2020-04-26       Impact factor: 4.241

6.  Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial.

Authors:  Daniel E Weiner; Luke Falzon; Line Skoufos; Angelito Bernardo; Werner Beck; Mengqi Xiao; Ha Tran
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-25       Impact factor: 8.237

Review 7.  High-volume online haemodiafiltration treatment and outcome of end-stage renal disease patients: more than one mode.

Authors:  Helmut Schiffl
Journal:  Int Urol Nephrol       Date:  2020-06-02       Impact factor: 2.370

Review 8.  Current approaches to middle molecule removal: room for innovation.

Authors:  Ikuto Masakane; Kenji Sakurai
Journal:  Nephrol Dial Transplant       Date:  2018-10-01       Impact factor: 5.992

Review 9.  Chronic inflammation in end-stage renal disease and dialysis.

Authors:  Gabriela Cobo; Bengt Lindholm; Peter Stenvinkel
Journal:  Nephrol Dial Transplant       Date:  2018-10-01       Impact factor: 5.992

Review 10.  Expanded haemodialysis: from operational mechanism to clinical results.

Authors:  Claudio Ronco; Nicola Marchionna; Alessandra Brendolan; Mauro Neri; Anna Lorenzin; Armando J Martínez Rueda
Journal:  Nephrol Dial Transplant       Date:  2018-10-01       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.